Quest Diagnostics CEO on Using Blood Testing for Alzheimer’s Diagnosis

Summary

Jim Davis, CEO of Quest Diagnostics, discusses the company's growth drivers after a raised 2026 outlook and record-high shares. He highlights chronic care testing demand, rapid growth in consumer health testing partnerships, Alzheimer's blood-based biomarkers, and a growing oncology testing business. Davis also outlines ongoing M&A priorities in hospital outreach and capability-enhancing deals.

• Quest Diagnostics raised its 2026 adjusted profit and revenue outlook; shares hit a record high.
• Growth is driven by chronic care testing and consumer health/prevention testing.
• The consumer health segment is about $250 million, grew over 30%, and is expected to grow over 20%.
• Alzheimer's blood-based biomarkers can detect disease earlier than PET/CT or MRI.
• New Alzheimer's therapies work best early, increasing the need for early diagnosis.
• Quest has the largest anatomical pathology business and a growing oncology portfolio.
• Haystack minimal residual disease testing detects residual cancer after surgery or chemotherapy.
• Quest continues to pursue hospital outreach and capability-enhancing M&A.